Surface Oncology

Surface Oncology is developing next generation immunotherapies that target the immune-suppressive tumor microenvironment to attack cancer.

Industries

Biotechnology, Education

Headquarters

Cambridge, United States

Stage

Post IPO Equity

Employees

51-200

Links

Org chart

Robert Ross

CEO, Director

Collapse

Jessica Fees

CFO

Henry Rath

Chief Business Officer

Vito Palombella

Chief Scientific Officer

Alison O’Neill

Chief Medical Officer

Lisa Mcgrath

Chief People Officer

Benjamin Lee

VP, Translational Science

Chandra Adams

VP, Legal

Shannon Rourke Devens

VP, Clinical Development Operations

Teams

View all

+13

Board of Directors

16 members

Leadership Team

9 members

CEO and Executive Team

6 members

Discover similar companies

Evelo Biosciences

Cambridge, United States · Post IPO Debt

Senti Biosciences

South San Francisco, United States · Post IPO Equity

Fulcrum Therapeutics

Cambridge, United States · Post IPO Equity

Regulus Therapeutics

San Diego, United States · Post IPO Equity

Trevena

King of Prussia, United States · Post IPO Equity

Celularity

Florham Park, United States · Post IPO Equity

Century Therapeutics

Philadelphia, United States · Post IPO Equity

Passage Bio

Philadelphia, United States · Post IPO Equity

SpringWorks Therapeutics

Stamford, United States · Post IPO Equity

Ovid Therapeutics

New York, United States · Post IPO Equity

Jounce Therapeutics

Cambridge, United States · Post IPO Equity

Arbutus Biopharma

Warminster, United States · Post IPO Equity

The Org
helps you hire
great candidates

It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.